We're delighted to announce the start of an international research project under the European Consortium for Continuous Pharmaceutical Manufacturing (ECCPM). The collaborative efforts from industrial and scientific partners aim to develop continuous manufacturing practices and improve the quality and cost-effectiveness of nanoparticles-based drug products. Utilizing cutting-edge technology and innovative techniques, we're paving the way for a new era of production and nanomedicine.
Pour se démarquer des autres sous-traitants pharmaceutiques, Skyepharma fait le choix de l’innovation. Un choix audacieux que nous expliquent David Lescuyer, président et directeur général, et Laurent Rigaudeau, directeur commercial.